Updated on 8 October 2015
Cambridge-based Domainex Ltd has appointed Shin Kitaoka of BioGemini Ltd. to provide advice on expansion into the Japanese market. The release indicates that Kitaoka has over 35 years of experience in the pharmaceutical industry.
He is an expert on drug development in Japan and is a well-known speaker on issues concerning drug development and partnerships with Japanese companies. Kitaoka has experience in all therapeutic areas and a special interest and strong track record in oncology and respiratory diseases, and in preclinical and early stage clinical assets.
Prior to BioGemini, Kitaoka spent 13 years at SmithKline Beecham in Japan then at GSK in London. He led business development in Japan for Glaxo and was the first Japanese national to be employed at the company's London headquarters.
Commenting on his appointment as a Japan Strategist for Domainex, Kitaoka said, "Domainex has a highly attractive set of technologies and a huge experience base that can address unmet drug discovery needs for the Japanese market, as well as a range of proprietary programs. I am looking forward to supporting the Domainex team's expansion into Japan so that Japanese companies can benefit from their expertise."
Dr. Thomas Mander, COO of Domainex commented, "We are delighted to welcome Shin to Domainex. He is a tireless ambassador for the companies he represents and he has an extensive network of business relationships with senior decision-makers at a range of Japanese pharmaceutical and life science organizations. We are looking forward to Shin helping us to introduce our drug discovery assets and services to the Japanese market."